公开(公告)号：US09694016B2

公开(公告)日：2017-07-04

申请号：US14774431

申请日：2014-03-13

Applicant: Novartis AG

Inventor： Robert John Aversa ,  Paul Andrew Barsanti ,  Matthew Burger ,  Michael Patrick Dillon ,  Alan Dipesa ,  Cheng Hu ,  Yan Lou ,  Gisele Nishiguchi ,  Yue Pan ,  Valery Polyakov ,  Savithri Ramurthy ,  Alice Rico ,  Lina Setti ,  Aaron Smith ,  Sharadha Subramanian ,  Benjamin Taft ,  Huw Tanner ,  Lifeng Wan ,  Naeem Yusuff

IPC: C07D413/14 ,  C07D403/14 ,  C07D403/12 ,  C07D401/04 ,  A61K31/5377 ,  C07D413/04 ,  A61K31/541 ,  A61K45/06 ,  C07D213/74 ,  C07D237/20 ,  C07D239/42 ,  C07D239/47 ,  C07D239/48 ,  C07D277/42 ,  C07D401/12 ,  C07D403/04 ,  C07D413/12 ,  C07D417/12 ,  C07D493/10 ,  C07D401/14 ,  C07D405/14 ,  C07D213/75 ,  C07D233/88 ,  C07D405/04 ,  C07D405/12 ,  C07D241/20 ,  C07D471/04 ,  C07D487/04 ,  C07D263/58 ,  C07D491/107 ,  C07D493/04 ,  C07D495/04 ,  C07D498/08 ,  C07D513/04 ,  A61K31/5375 ,  C07D213/81 ,  C07D213/82 ,  C07D213/84 ,  C07D237/22 ,  C07D409/14 ,  C07D491/048

CPC classification number: A61K31/5377 ,  A61K31/444 ,  A61K31/501 ,  A61K31/5375 ,  A61K31/541 ,  A61K45/06 ,  C07B59/002 ,  C07B2200/05 ,  C07D213/74 ,  C07D213/75 ,  C07D213/81 ,  C07D213/82 ,  C07D213/84 ,  C07D233/88 ,  C07D237/20 ,  C07D237/22 ,  C07D237/24 ,  C07D239/42 ,  C07D239/47 ,  C07D239/48 ,  C07D241/20 ,  C07D263/58 ,  C07D277/42 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D491/04 ,  C07D491/048 ,  C07D491/08 ,  C07D491/107 ,  C07D493/04 ,  C07D493/10 ,  C07D495/04 ,  C07D498/08 ,  C07D513/04

Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.

公开(公告)号：US20130336965A1

公开(公告)日：2013-12-19

申请号：US13897927

申请日：2013-05-20

Applicant: Novartis AG

Inventor： Matthew Burger ,  Joseph E. Drumm, III ,  Gisele Nishiguchi ,  Alice Rico ,  Robert Lowell Simmons ,  Benjamin Taft ,  Huw Tanner

IPC: C07D213/81 ,  A61K31/506 ,  A61K31/4545 ,  A61K31/444 ,  A61K31/4439 ,  A61K45/06 ,  C07D405/14 ,  C07F9/6558 ,  C07D401/14 ,  C07D417/12 ,  C07D409/14 ,  C07D417/14 ,  A61K31/675 ,  C07D401/12

CPC classification number: A61K31/506 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/675 ,  A61K45/06 ,  C07D213/81 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D407/14 ,  C07D409/14 ,  C07D417/12 ,  C07D417/14 ,  C07F9/65583

Abstract: The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.

公开(公告)号：US09173883B2

公开(公告)日：2015-11-03

申请号：US14402541

申请日：2013-05-20

Applicant: Novartis AG

Inventor： Matthew Burger ,  Joseph E. Drumm, III ,  Gisele Nishiguchi ,  Alice Rico ,  Robert Lowell Simmons ,  Benjamin Taft ,  Huw Tanner

IPC: C07D403/12 ,  C07D401/14 ,  C07D401/12 ,  C07D403/14 ,  C07D407/14 ,  C07D409/14 ,  C07D417/12 ,  C07D417/14 ,  C07D213/81 ,  C07D405/14 ,  A61K31/506 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/675 ,  A61K45/06 ,  C07F9/6558

CPC classification number: A61K31/506 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/675 ,  A61K45/06 ,  C07D213/81 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D407/14 ,  C07D409/14 ,  C07D417/12 ,  C07D417/14 ,  C07F9/65583

Abstract: The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.

Abstract translation: 本发明提供式（A）化合物：如本文所述，及其药学上可接受的盐，对映异构体，旋转异构体，互变异构体或外消旋体。 还提供了使用式I化合物治疗PIM激酶介导的疾病或病症的方法和包含这些化合物的药物组合物。